Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EPS (Weighted Average and Diluted) (2020 - 2025)

Arcadia Biosciences (RKDA) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with $0.62 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 152.54% year-over-year to $0.62, compared with a TTM value of -$4.81 through Sep 2025, down 56.17%, and an annual FY2024 reading of -$5.17, up 54.21% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.62 for Q3 2025 at Arcadia Biosciences, up from -$3.26 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.33 in Q2 2023 and bottomed at -$27.3 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.35, with a median of -$1.89 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 7454.55% in 2022, then soared 371.43% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$27.3 in 2021, then surged by 37.03% to -$17.19 in 2022, then surged by 88.48% to -$1.98 in 2023, then tumbled by 105.56% to -$4.07 in 2024, then skyrocketed by 115.23% to $0.62 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RKDA at $0.62 in Q3 2025, -$3.26 in Q2 2025, and $1.9 in Q1 2025.